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Sepsis is a highly lethal syndrome resulting from dysregulated immune and
metabolic responses to infection, thereby compromising host homeostasis. Activation
of the hypothalamic–pituitary–adrenal (HPA) axis and subsequently adrenocortical
glucocorticoid (GC) production during sepsis are important regulatory processes to
maintain homeostasis. Multiple preclinical studies have proven the pivotal role of
endogenous GCs in tolerance against sepsis by counteracting several of the sepsis
characteristics, such as excessive inflammation, vascular defects, and hypoglycemia.
Sepsis is however often complicated by dysfunction of the HPA axis, resulting from
critical-illness-related corticosteroid insufficiency (CIRCI) and GC resistance. Therefore,
GCs have been tested as an adjunctive therapy in sepsis and septic shock in different
randomized clinical trials (RCTs). Nonetheless, these studies produced conflicting results.
Interestingly, adding vitamin C and thiamin to GC therapy enhances the effects of GCs,
probably by reducing GC resistance, and this results in an impressive reduction in sepsis
mortality as was shown in two recent preliminary retrospective before–after studies.
Multiple RCTs are currently underway to validate this new combination therapy in sepsis.
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THE SEPSIS BURDEN
Sepsis is defined as a life-threatening organ dysfunction due to a dysregulated host response to an
infection (1). In 2017, theWorld Health Organization (WHO) has labeled sepsis as the most urgent
unmet medical need of our times (2). Despite that the term “sepsis” was already introduced by
Hippocrates in the fourth century BC and innumerable patients worldwide have died of it, sepsis
is not well-known in the general population (2). A recent study has proven that the incidence
of sepsis was even severely underestimated and is at least twice of what was previously thought
(3). The annual burden of sepsis is now estimated to be 48.9 million sepsis cases with 11 million
deaths worldwide, representing 19.7% of all global deaths (3). The previous estimates of sepsis
incidence and mortality relied on hospital administrative databases, excluding patients who were
never admitted to hospitals, e.g., in developing countries. Moreover, the old estimates were based
on middle- and high-income countries, and many studies were restricted to adults as a result of a
paucity of data for children (3).
During the beginning of the twenty-first century, the frequency of sepsis has increased, while
mortality rates decreased. The increasing frequency reflects the increasing aging population who
has impaired immunity as a result of immunosenescence, whereas the sepsis mortality decrease is
thought to be a consequence of improved health care in hospitals and ICUs (4). Unfortunately, the
decreasedmortality rates are not a consequence of new therapies or a better understanding of sepsis
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pathobiology based on preclinical studies. This failure in progress
of sepsis research is not a result of a lack of studies. On the
contrary, sepsis research in mice has yielded many new potential
therapies. However, none of these strategies have successfully
penetrated to the bedside (5). Therefore, management of sepsis
patients is supportive rather than curative and essentially relies
on antibiotic treatment, hemodynamic stabilization, and support
of failing organs, e.g., ventilation of the lungs. Next to the obvious
global health problem, sepsis also poses a high economic burden.
The mean hospital-wide cost of a sepsis patient is estimated to
be $ 32.421 (6). Moreover, patients who survive sepsis often have
long-term cognitive impairment and functional disability with a
permanent high risk of mortality after discharge (7).
Sepsis is caused by an infection, and the primary site of
infection is most commonly the respiratory tract (64%), followed
by the abdomen (20%) and urogenital tract (14%). Intra-
abdominal infection is associated with the highest mortality
(30.7%) (8). In most cases, sepsis is caused by gram-positive or
gram-negative bacteria, but also fungi, viruses, and parasites can
cause sepsis. Preclinical models of sepsis can be classified into
three categories based on the mechanism involved, including
administration of a cytokine or toxin [e.g., tumor necrosis
factor (TNF) or lipopolysaccharide (LPS)], administration of
a viable pathogen (e.g., E. coli), or disruption in the animal’s
protective barrier allowing for bacterial invasion [e.g., cecal
ligation and puncture (CLP)] (9). The latter is considered as
the gold standard for sepsis research (10). Nevertheless, in the
current animal models of sepsis, most deaths occur within the
first 5 days, thereby representing only the early deaths of sepsis
resulting from the initial hyper-inflammatory state. In many
cases, sepsis patients can survive the initial hyper-inflammatory
state and succumb from subsequent nosocomial infections with
pneumonia being the most common etiology (11, 12). Indeed,
as the septic condition persists, the host immunologic response
shifts from a hyper-inflammatory state to anti-inflammatory in
which the patient is immunocompromised. A preclinical model
studying late-onset immunosuppression in sepsis is the “two-hit
model” of sepsis in which a primary sublethal infection, such
as CLP, impairs the immune system, thereby rendering the host
more susceptible to secondary infections, such as pneumonia
(12, 13).
HPA AXIS AND GR
The immune system protects the host against infections by
eliminating the infectious agents (i.e., resistance mechanism).
However, pathogen eradication is frequently associated with
collateral tissue damage and inflammation, which potentially
decreases host fitness (14). Activation of the hypothalamic–
pituitary–adrenal (HPA) axis by immune cell-derived cytokines
is an important regulatory process to maintain homeostasis and
survive the life-threatening impact of excessive inflammation on
the host (i.e., tolerance mechanism) (14).
The HPA axis is regulated by a circadian and ultradian
rhythm characterized by peak levels during the active phase
which is in the morning in humans and in the beginning
of nighttime in nocturnal animals such as mice. The activity
of the HPA axis is further increased upon physiological (e.g.,
activated immune system) and emotional stress (15). Cytokines
such as interleukin 1β (IL-1β), TNF, and IL-6 are potent inducers
of the HPA axis (Figure 1) (16). The hypothalamus secretes
corticotropin-releasing hormone (CRH) which subsequently
induces secretion of adrenocorticotropic hormone (ACTH) by
the anterior pituitary and finally glucocorticoids (GCs; cortisol in
humans and corticosterone in rodents) from the adrenal cortex
using cholesterol as a substrate. The lipophilic GCs are then
released into the bloodstream, diffuse through cell membranes
to bind cytosolic glucocorticoid receptor (GR), which is
constitutively and ubiquitously expressed throughout the body.
Fine-tuning of bloodGC levels is regulated by a negative feedback
loop, whereby increased GC levels inhibit the HPA axis at
different points (17). Adrenal GC production controls total GC
levels in the circulation, but extracellular binding proteins and
intracellular enzymes regulate GC activity locally. In plasma, a
large proportion of circulating GC is bound with corticosteroid-
binding globulin (CBG) or albumin, thereby leaving only
∼5% of circulating GC in a free, biological active form. At
inflammatory sites, neutrophil elastases can cleave CBG, thereby
liberating free GC at the site of inflammation. Within cells, 11β-
hydroxysteroid dehydrogenase (11β-HSD1/2) enzymes regulate
the interconversion of bioactive cortisol/corticosterone and
inactive cortisone/11-dehydrocortisone. Inflammatory cytokines
can regulate the expression of the 11β-HSD enzymes, thereby
modulating GC activity locally (18).
In the absence of ligand, the GR is primarily located in
the cytoplasm in a large chaperone complex. Upon ligand
binding, GR undergoes a conformational change leading to
partial dissociation from the chaperone complex exposing its
two nuclear localization signals (NLS). This leads to nuclear
translocation (NTL) of the GR, where it can interact with
other proteins and DNA to influence gene expression (19). GR
regulates gene expression of up to 20% of the genome by working
as a monomer or as a homodimer (18). In mouse liver under
endogenous GC levels, GR binds to DNA more frequently as a
monomer than as a dimer. As a monomer, GR interacts with
DNA by binding to GC response element (GRE) half-sites. If a
binding site for another transcription factor (TF) is nearby the
half site, both elements may act as a composite site where there is
an interaction (positive or negative) between the GR monomer
and the other TF (20). Alternatively, two GR monomers can
also interact with DNA by binding to inverted negative GREs
(IR-nGREs) to specifically repress gene transcription upon GR
binding by recruiting corepressors and histone deacetylases (21).
Administration of supra-physiological GC doses in contrast
favors GR dimer binding at GREs at the cost of monomer
binding (22). Binding of GR homodimers to GRE sequences
leads to an enhancement of gene expression (also referred to as
transactivation) (22). These data indicate that GR monomers are
more important for the physiological functions of GR, whereas
GR dimers are important for their pharmacological and perhaps
stress functions (22). GR can also occupy specific genome regions
indirectly in amechanism known as tethering. Tethering involves
physical interaction of the monomeric GR with another TF, such
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FIGURE 1 | Schematic representation of the hypothalamic–pituitary–adrenal
(HPA) axis. Upon circadian rhythm, stress, and inflammatory cytokines, the
hypothalamus secretes corticotropin-releasing hormone (CRH), stimulating the
pituitary to release adrenocorticotropic hormone (ACTH), which in turn induces
cortisol (human) or corticosterone (rodents) by the adrenal cortex. These
glucocorticoids in turn negatively regulate the activity of the HPA axis via the
paraventricular nucleus (PVN) of the hypothalamus and the anterior pituitary, or
indirectly by decreasing the expression of inflammatory cytokines. Figure
created with BioRender.com.
as activator protein 1 (AP-1) and NF-κB (23). These interactions
influence the DNA binding, cofactor recruitment, and gene
transcription of the involving TF. Besides the genomic effects,
GCs also exert rapid non-genomic effects that do not require
transcription processes or protein synthesis (24).
ROLE OF ENDOGENOUS GCs IN SEPSIS
To establish whether activation of the HPA axis is essential
for survival of sepsis, several animal studies were performed.
Disrupting the HPA axis surgically (by removal of either the
pituitary gland or adrenal cortex) or pharmacologically (with
the GR antagonist RU486) sensitizes mice for sepsis (25–27).
These data are in accordance with human studies showing that
patients with Addison’s disease, i.e., showing primary adrenal
insufficiency and hypocortisolism, have an increased risk of
death following infections (28). In contrast, overexpression of
GR leads to reduced inflammatory responses and increased
survival following endotoxic shock (29). SPRET/Ei mice, which
are known for their resistance for endotoxic shock, display a
combination of increased GR levels and overactivation of their
HPA axis (30), and this is associated with higher levels of the GR
inducible gene Tsc22d3 encoding the GC-induced leucine zipper
(GILZ) protein (31). RU486 pretreatment or adrenalectomy
abolishes the resistant phenotype of SPRET/Ei mice.
FIGURE 2 | The essential roles of glucocorticoids to tolerate sepsis. In sepsis
patients, the immune system is activated to eliminate the infectious agents;
however, if not properly balanced, pathogen eradication is associated with
excessive inflammation and endothelial barrier dysfunction leading to organ
failure. Dysregulated immune responses are also accompanied with changes
in metabolism, such as hypoglycemia. Glucocorticoids are induced upon
infections to maintain homeostasis and tolerate the life-threatening impact of
sepsis on the host.
The essential role for GCs in survival of sepsis is thought to be
the result of their anti-inflammatory, vascular, and gluconeogenic
effects (Figure 2) (32).
Effect of GR Signaling on Inflammation
Activation of the HPA axis is clearly important in the protection
against inflammation. As the GR is an ubiquitously expressed
ligand-dependent transcription factor, it can regulate many
different gene networks, each uniquely determined by particular
cellular and physiological contexts (33). To precisely dissect
mechanisms involved in a physiological process, cell-specific GR
deletion may render information on its role in a particular cell
type. Indeed, cell- or tissue-specific deletion or inhibition of the
GR has demonstrated the crucial role for GR in dampening the
inflammatory response during sepsis in different cells or tissues
(see Table 1).
In the past, the immune suppressive effects of GCs were
believed to be the result of monomeric GR-mediated tethering
to key inflammatory transcription factors such as NF-κB and
AP-1. However, the pivotal role of GR-mediated transrepression
as a mechanism to limit inflammation has been challenged
by several studies using dexamethasone as a synthetic ligand
for the GR. By inhibiting de novo protein synthesis by
use of cycloheximide, dexamethasone-dependent repression of
multiple mRNAs (IL-8, CSF2, CXCL1) was blocked. This implies
repressive mechanisms involving gene transcription. Conversely,
other pro-inflammatory mRNAs (e.g., TNF, ICAM1) showed
dexamethasone-dependent repression that was unaffected by
cycloheximide and thus implies repressive mechanisms involving
classical transrepression (46). The pro-inflammatory mRNAs
showing attenuated repression by dexamethasone in the presence
of cycloheximide were significantly more repressed and were
more potently repressed compared to those mRNAs showing
cycloheximide-independent repression, thereby indicating the
primacy of GR-mediated transactivation as a predominantly
anti-inflammatory mechanism. In vivo evidence supporting a
role for GR-mediated transactivation in mediating the anti-
inflammatory effects of GCs was provided by using GRdim/dim
mice characterized by a defective GR dimerization yet an
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TABLE 1 | Implications of cell-specific GR deletion on sepsis progression.
Tissue/cell GR deletion Effect of GR deletion in sepsis model References
Liver shRNA-GR Excessive liver and systemic inflammation
Increased mortality (CLP)
(34)
IEC Villin cre Increased ISG expression in gut, intestinal permeability
Increased mortality (LPS, TNF)
(35, 36)
Skeletal and cardiac muscle Mck cre Reduced muscle atrophy (LPS) (37)
Vascular smooth muscle SM22-α cre Small trend toward increased mortality (LPS) (38)




Myeloid cells/macrophages LysM cre Excessive systemic inflammation, ALI
Increased mortality (LPS)
(36, 39–41)
Thymocytes/T-cells Lck cre Resistance to CLP-induced thymocyte apoptosis
Increased mortality (CLP)
(42)
DCs CD11c cre Excessive systemic inflammation (IL-12)
Increased mortality (LPS)
(43)
NK cells Ncr1 cre Increased IFN-γ production, spleen immunopathology
Increased mortality (CMV, LPS)
(44, 45)
IEC, intestinal epithelial cell; CLP, cecal ligation and puncture; LPS, lipopolysaccharide; TNF, tumor necrosis factor; ISG, interferon-stimulated genes; NO, nitric oxide; ALI, acute lung
injury; DC, dendritic cell; NK, natural killer; CMV, cytomegalovirus.
intact monomer profile (47). Several studies showed that GR
homodimers are indispensable for the GC-mediated protection
in acute inflammation. Indeed, GRdim/dim mice are highly
susceptible for TNF-induced mortality as these mice fail to
induce theDusp1 gene, coding for MAPK phosphatase 1 (MKP1)
(48). Moreover, GRdim/dim mice display poor control of intestinal
STAT1 resulting in excessive necroptosis in the gut after TNF
injection (35). GR dimerization is also required for survival
against LPS- and CLP-induced shock via downregulation of
Il-1β (41) and upregulation of SphK1 (40) in macrophages.
GRdim/dim mice present impaired lung function upon LPS
challenge under intensive care treatment, possibly through
regulation of Osteopontin (Opn) in lung tissue (49). So, GR
dimers have the potential to control acute inflammation because
they induce dimer-dependent genes, the product of which
has anti-inflammatory functions (e.g., SPHK1, MKP1) or by
repressing pro-inflammatory genes (e.g., Stat1, Il-1β) in a dimer-
dependent way.
Some researchers feel it counterintuitive to use immune
suppressive drugs, such as GCs, in patients with severe infections.
However, in spite of the well-known anti-inflammatory actions
of GCs, it is becoming increasingly clear that GCs also display
immune-enhancing effects in sepsis. A better comprehension of
the impact of GCs on the immunological effects may provide
rationale for their use in sepsis.
Myeloid Cells
Myeloid-specific deletion of GR leads to an increased
susceptibility to LPS-induced mortality (39–41). In contrast,
targeting dexamethasone specifically to macrophages by use
of an anti-CD163-dexamethasone conjugate increases the
anti-inflammatory potential of dexamethasone resulting in
enhanced protection against LPS (50). The essential functions
of myeloid GR in protecting against LPS-induced mortality
is to inhibit pro-inflammatory mediators, such as IL-1β (41)
and p38 MAPK (39), as well as to induce the expression of
anti-inflammatory genes, such as SphK1 (40). In addition to the
well-known anti-inflammatory actions of GR, GCs have been
described to enhance the phagocytic and bacterial killing capacity
of monocytes/macrophages, which is off course of high value in a
bacterial environment like sepsis. In vitro, incubation of human
monocytes with dexamethasone augments the phagocytosis of
various particles, such as Staphylococcus aureus, latex beads,
zymosan, acLDL and myelin, and this effect could be completely
blocked by adding the GR antagonist RU486 during culture (51).
Not only the phagocytosis of S. aureus bacteria is augmented but
also the killing of these bacteria is increased by dexamethasone
(51). Equally so, peripheral blood monocytes derived from sepsis
patients who were treated with hydrocortisone in vivo display
enhanced phagocytosis in an ex vivo assay, whereas the pro- and
anti-inflammatory responses are attenuated in these patients
(52). Also in vivo, there is evidence for the immune-enhancing
effects of GCs. Administration of low-dose GCs in mice
challenged with E. coli decreases the bacterial burden of these
mice (53). Overexpression of the GR-inducible protein GILZ in
the whole body (54) or restricted specifically to macrophages (55)
protects mice against CLP-induced sepsis by limiting systemic
inflammation, while bacterial clearance is increased in these
mice. It would be interesting to study whether GRLysmcre mice are
also sensitized in bacterial sepsis models such as the CLP model
and, if so, whether this could be linked to an increased bacterial
burden along with increased inflammation. Next to enhancing
phagocytosis of bacteria, GCs also enhance the clearance of
apoptotic cells and cell debris, i.e., efferocytosis, which is
important to start tissue repair [see recent review on this topic;
(56)]. A possible mechanism explaining the apparently opposing
effects of GCs in sepsis is by a GC-induced differentiation of a
specific anti-inflammatory subtype of monocytes, which seems
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to be actively involved in resolution of inflammatory reactions
instead of a global suppression of monocytic effector functions
as was originally thought (57).
T-Cells
Using GRLckcre mice in whom thymocytes lack the GR, it has been
demonstrated that GR signaling is required for proper selection
of thymocytes and absence of GR signaling in thymocytes impairs
thymocyte development resulting in generation of functionally
compromised T-cells (58). The resulting immunocompromised
state renders these mutant mice more susceptible for CLP-
induced sepsis (42). In the latter study, only survival curves
are provided, but neither the inflammation state nor bacterial
burden of the septic animals is shown. Further evidence for the
role of GCs in enhancing T-cell responses was recently provided
by Shimba et al. They demonstrate that endogenous GCs drive
IL7-R expression in a diurnal fashion which induces T-cell
homing to peripheral lymphoid organs via CXCR4 expression,
thereby enhancing the adaptive immune response against Listeria
monocytogenes infection (59).
Dendritic Cells (DCs)
To explore the function of GR on DCs in sepsis, mice with
selective deletion of the GR in DCs (GRCD11ccre) were subjected
to LPS injection (43). These mutant mice are much more
susceptible to LPS-induced shock as GR on DCs is important
to reduce IL-12 production, a cytokine that causes secretion
of other inflammatory mediates (43), probably by skewing DC
maturation toward a tolerogenic profile by inducing GILZ (60).
In addition, endogenous GCs produced upon LPS stimulus
causes the death of a subset of DCs that are the primary producers
of IL-12, thereby inducing LPS tolerance (43). As DC cell loss is a
hallmark for sepsis-induced immune dysfunction, its suppression
by GCs may contribute to post-septic immunosuppression,
especially given the essential role for DCs in antigen presentation.
Therefore, it would be informative to test these mutant mice in a
bacterial model of sepsis and check whether bacterial clearance
is affected.
Natural Killer Cells (NK Cell)
Deletion of GR specifically on NRC1+ cells (i.e., NK cells and
type I innate lymphoid cells) renders mice more susceptible
to both mouse cytomegalovirus (CMV) (44) and LPS-induced
mortality (45). The endogenous GCs produced in response
to infection protect by inducing PD-1 on NK cells, thereby
controlling the production of IFN-γ and leading to tolerance
in both infectious conditions (44). Interestingly, this GC-PD1
pathway only limits the production of IFN-γ, but viral clearance
is not compromised in these mice (44). These data suggest that
GCs are able to decouple the IFN-γ-producing function of NK
cells from their cytotoxic function. The mechanism underlying
this decoupling effect of GCs needs further investigation. It
would be interesting to evaluate the role of this pathway in
other infectious conditions as NK cells are also known to be
involved in the host immune response against bacterial and
fungal pathogens. Endogenous GCs are also important for NK
cell function in patients with respiratory infections. Patients
with Addison’s disease display a significantly decreased NK
cell cytotoxicity, thereby compromising early recognition and
elimination of virally infected cells. This impaired antiviral
immune defense may contribute to the increased rate of
respiratory infections and death typically observed in these
patients (28).
In contrast to the aforementioned studies, other studies show
an impairment of phagocytosis or pathogen clearance upon
GC addition (61–64). Possible explanations for this discrepancy
include the dose and type of GC used, duration of treatment, the
activation state and origin of the cells (in vitro differentiated or
obtained from tissues), and the phagocytosis assay used.
To conclude, the abovementioned studies clearly demonstrate
a role for GCs in dampening the exaggerated immune response,
while at the same time pathogen clearance can be preserved.
Nevertheless, further studies are warranted to fully understand
the mechanism and consequences of GCs in sepsis and to predict
the risks associated with high levels of stress-induced endogenous
GCs or with exogenous GC treatments. Based on the clinical trials
using GC administration as an adjunctive therapy for sepsis (see
High- and Low-Dose GC Therapy), it seems that the main factors
determining the outcome of GC therapy on the infection include
the dose, duration, and timing of GC therapy.
Effect of GR Signaling on Vascular
Function
GCs also regulate different aspects of endothelial physiology
during sepsis. In sepsis patients, the vascular reactivity and
endothelial barrier function are impaired, and this contributes to
adverse outcome (65). Possible mechanisms for reduced vascular
tone include (i) induction of nitric oxide (NO) synthase, which
in turn produces relaxation of vascular smooth muscle tone
resulting in hypotension, and (ii) reduction of vasoconstrictor
response to catecholamines.
Adrenalectomized mice show a much more severe form of
circulatory shock after LPS injection, which is characterized
by a profound drop in blood pressure and lack of response
to intravenous noradrenaline injection (66). Adrenalectomized
mice lack production of both GCs (derived from the adrenal
cortex) and catecholamines (derived from the adrenal medulla).
However, the synthetic GC dexamethasone is able to restore
this hyporeactivity to noradrenaline injection, probably resulting
from rapid non-genomic effects according to the authors as
these effects are seen as early as 10min after dexamethasone
administration (67). On the other hand, this response seems to
be dimer dependent, as GRdim/dim mice display an aggravated
hemodynamic instability after LPS challenge, reflected by
a significantly increased need for norepinephrine to reach
hemodynamic stability (49). GCs also enhance vasoconstrictor
response to catecholamines in septic patients, and this effect was
stronger in patients with adrenal insufficiency (68). Furthermore,
GCs act as a negative regulator of NO release and deletion of
GR in endothelial cells renders mice more susceptible for LPS-
induced shock through increased hemodynamic instability (38).
Repeated challenges with small doses of LPS result in tolerance
to peripheral vascular hyporeactivity and associated mortality
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caused by subsequent injection with a higher dose of LPS. This
tolerance could be explained by reduced induction of iNOS
due to the elevated endogenous GC levels (69). Lastly, GR in
macrophages is necessary to induce SphK1, which has a critical
role in maintaining endothelial barrier function. Dexamethasone
pretreatment protects against LPS-induced acute lung injury via
maintaining the endothelial barrier integrity in the lungs (40).
Effect of GR Signaling on Glucose
Homeostasis
Disturbance in glucose homeostasis is a typical feature of sepsis.
In the initial phase of sepsis, hyperglycemia is observed resulting
from insulin resistance, altered glycogen metabolism, and/or
increased gluconeogenesis. This allows redirection of glucose to
immune cells supporting aerobic glycolysis and thus immune
function. In a later stage of sepsis, hypoglycemia could be
observed presumably resulting from depleted glycogen storages,
increased peripheral usage of glucose, anorexia, and/or decreased
gluconeogenesis (70).
The GR plays a key role in glucose homeostasis by regulating
the transcription of genes coding for gluconeogenic enzymes
such as Pck1 and G6Pc and by reducing the glucose uptake
(e.g., GC suppresses GLUT4 translocation to the membrane) and
glucose utilization (e.g., GC upregulates pyruvate dehydrogenase
kinase Pdk4) in skeletal muscle and white adipose tissue (71).
Pro-inflammatory cytokines following endotoxic shock exposure
has been identified to decrease expression of gluconeogenic
enzymes. Both the GC-responsive element (GRE) and the
cyclic adenosine monophosphate (cAMP)-responsive element
(CRE) were identified as critical cis-regulatory targets of the
pro-inflammatory cytokines (72). Specifically the expression
of nuclear receptor cofactor peroxisome proliferator-activator
receptor coactivator 1a (PGC1a), the molecular mediator of the
GRE/CRE synergism on the PEPCK promoter, was found to be
repressed in liver during endotoxic shock (72). Restoration of
PGC1a restored PEPCK expression in hepatocytes exposed to
pro-inflammatory signaling (72). In vivo, anti-TNF pretreatment
in mice challenged with LPS is able to maintain normal Pck1
transcription and enzyme activity, thereby identifying a role for
TNF as the mediator of LPS-induced Pck1 downregulation (73).
However, neutralization of TNF fails to prevent hypoglycemia
during endotoxemia (73). PEPCK was considered as the rate-
limiting enzyme for a long time, but a study published by Burgess
et al. surprisingly showed that hepatic PEPCK content alone
is only weakly influencing gluconeogenesis (74). This suggests
that other factors such as peripheral substrate supply, other
gluconeogenic enzymes, and/or hepatic energy metabolism must
coordinate with PEPCK expression to regulate gluconeogenesis
(74). Next to PEPCK, also G6Pase is found to be downregulated
after LPS (72) and CLP-induced sepsis (75). PGC1a is also
known to increase the expression G6Pase, providing an
extra possible mechanism in which inflammation represses
gluconeogenesis and promotes hypoglycemia (76). Furthermore,
ROS is able to repress G6Pase expression and pharmacological
inhibition of ROS restores G6Pc gene expression and counteracts
hypoglycemia in septic mice (75). It is thus plausible that
inflammation induces hypoglycemia by affecting simultaneously
multiple enzymes in the gluconeogenic pathway and GR is
necessary to counteract the inflammation-induced effects.
DYSFUNCTION OF THE HPA AXIS DURING
SEPSIS
CIRCI
It is clear from the abovementioned studies that activation of
the HPA axis and GC signaling are required for maintaining
homeostasis and eventually survival in sepsis. However, in many
critically ill patients, this homeostatic activation of adrenocortical
hormones is impaired. It has been estimated that dysfunction
of the HPA axis occurs in 10–20% of critically ill patients and
increases to 60% in patients with septic shock (77). Adrenal
necrosis and hemorrhage as a result of renal failure, shock,
or disseminated intravascular coagulation (DIC) may lead to
adrenal insufficiency (77). However, it seems that most patients
develop reversible dysfunction of the HPA axis caused by pro-
inflammatory mediators. In 2008, the term adrenal insufficiency
was replaced by the term “Critical Illness-Related Corticosteroid
Insufficiency” (CIRCI) (78) because adrenal insufficiency may
arise due to dysfunction at any point in the HPA axis, including
the hypothalamus, pituitary, and adrenal cortex. Indeed, direct
damage to the hypothalamus or the pituitary gland caused
by head injuries (79), the use of sedatives such as etomidate
(80), long-term treatment with exogenous GCs (81), or altered
metabolism of cortisol (34) may all affect the HPA-axis response
in critically ill patients. Lastly, the resistance of target tissues
to GCs, so-called glucocorticoid resistance (GCR), can also be
interpreted as an insufficiency of the HPA axis at the peripheral
level of target tissues (77). In the past, the diagnosis of adrenal
insufficiency was based on the measurement of total serum
cortisol or the change in the serum cortisol in response to 250
µg of ACTH (ACTH stimulation test). However, as CIRCI may
result from defects at multiple levels in the HPA axis and in the
periphery, the current diagnostic tools to identify patients with
CIRCI turned out to be inadequate (77).
Glucocorticoid Resistance in Sepsis
GCR is a well-known manifestation in sepsis and may contribute
to the failure of GCs to improve sepsis patients. GCR refers to the
inadequate response of the GR to regulate the transcription of
GR-responsive genes, despite seemingly adequate plasma cortisol
concentrations. Evidence for an association between the degree
of GC unresponsiveness and disease severity and mortality was
demonstrated in acute respiratory distress response (ARDS) (82)
and septic shock (83).
The mechanisms of GCR in sepsis, in theory, can be manifold
(Figure 3). Pro-inflammatory cytokines such as TNF have been
shown to decrease the GR-alpha expression (84). Reduced GR-
alpha levels are reported in several cell types derived from sepsis
patients (PBMC, liver, brain, muscle and lung) (85–87). However,
other studies displayed an increased expression of GR-alpha upon
inflammation (88, 89). Increased expression of the dominant-
negative isoform GR-beta has also been shown in sepsis (90);
however, increased GR-beta levels do not seem to correlate with
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FIGURE 3 | Mechanisms of glucocorticoid resistance (GCR) in sepsis. Pro-inflammatory cytokines and oxidative stress have shown to interfere with the GC signaling
pathway at multiple levels. This leads to an inadequate response of the GR to both endogenous (cortisol/corticosterone) and exogenous GCs to tolerate collateral
damage induced by sepsis. Vitamin C has been shown to restore the GR function by reverting the effect of oxidative stress on GR’s ligand- and DNA-binding capacity.
TF-BS, transcription factor binding site; GRE, GC-responsive element; NTL, nuclear translocation.
decreased GC responses in septic shock patients (83). Next, pro-
inflammatory cytokines such as IL-1 and oxidative stress may
hamper nuclear translocation (NTL) of GR upon dexamethasone
administration (88, 91). In an ex vivo model, reduced NTL of
the GR in patients with lethal ARDS was demonstrated despite
adequate levels of cortisol (82). This reduced NTL could possibly
be explained by reduced GC-binding capacity of the GR upon
endotoxin challenge (92), as GR ligand binding is necessary
to expose the nuclear localization signal (NLS). A possible
role for nitric oxide (NO) was found herein as prophylactic
administration of a NO synthase inhibitor blunted the LPS-
induced decrease in GR binding to GCs (93). Furthermore, GR
binding to DNA may be affected by oxidation of cysteine thiol
groups of the GR or by metal ions that have high affinity to thiol,
thereby reducing the efficacy of GCs (94, 95). Finally, the GR
cofactor PGC1a is found to be downregulated in septic liver (72)
and cells pretreated with TNF display a reshuffling of cofactor
p300 fromGR to NF-κB, thereby modulating the GR interactome
(96). PGC1a restoration or p300 overexpression restores GC
responsiveness (72, 96).
GCR has been considered by some researchers as another
good reason to treat sepsis patients with high stress doses of GCs
(77), whereas other groups used GCR as an argument against the
use of GCs in sepsis (34, 97). On the one hand, GCR obviously
limits the therapeutic use of GCs, since there is insufficient GR
functioning. In the TNF-induced SIRS model, dexamethasone
only protects when given before TNF injection. However, when
dexamethasone was given shortly after TNF injection, it is unable
to protect (84). These results may imply that the inflammatory
environment leads to reduced functioning of the GR. On the
other hand, GC treatment further suppresses GR expression as
was shown in human biopsy samples and this may predispose the
patients to excessive inflammation, organ failure, and eventually
death (34). Understanding the mechanisms underlying GCR
opens avenues for reverting GCR in sepsis and applying GCs
therapeutically. One of the most promising candidates to revert
GCR is the antioxidant L-ascorbic acid, or vitamin C. Vitamin
C has been shown to restore the GR function by reverting
the effect of oxidative stress on GR’s ligand- and DNA-binding
capacity (98). Preclinical studies demonstrated the synergistic
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effect of adding vitamin C to GC therapy on endothelial barrier
function (99) and intestinal mucosa injuries in sepsis models
(100). Furthermore, two recent retrospective before–after clinical
trials evaluating this combination therapy in the treatment of
septic shock and severe pneumonia look very promising (101,
102). This combination therapy will be further discussed below.
Alternatively, administration of GC-induced proteins, such as
GILZ, allows working downstream of the GR and thus provides
a potential mechanism to circumvent GCR in sepsis (54, 55,
103). Injection of a TAT-GILZ fusion construct into mice has
been shown to protect against LPS-induced endotoxemia (31).
The TAT peptide is a cell-penetrating peptide that can be used
to overcome the lipophilic barrier of the cell membrane and
deliver large molecules and small particles inside cells. Whether
this fusion construct could circumvent GCR remains to be
studied. Another way of increasing GILZ expression in cells is via
administering other factors, such as vitamin D3, which is known
to increase GILZ expression in DCs (104).
A THERAPEUTIC ROLE FOR EXOGENOUS
GCs IN SEPSIS?
High- and Low-Dose GC Therapy
GCs as an adjunctive treatment for sepsis remain one of the most
controversial items in sepsis despite more than four decades of
investigations. The rationale for the use of GCs in sepsis is that
GCs attenuate both the pro- and anti-inflammatory responses
typically seen in sepsis. Besides regulating inflammation, GCs
also increase the vasoactive tone, thereby amplifying the
effect of vasopressors during septic shock (78). Between 1976
and 2018, 24 randomized clinical trials (RCTs) have been
published reporting the 28-day mortality or hospital mortality
of GC therapy in sepsis or septic shock (105). These studies
exhibited conflicting results. Even the results of multiple
meta-analyses were contradictory with some showing survival
advantage (106, 107), whereas others did not find any survival
benefit (108, 109).
The first large clinical trials on the use of GCs in sepsis
involved high dose of GCs in the management of septic shock.
This early study showed that bolus injection of high doses of
GCs (3 mg/kg dexamethasone or 30 mg/kg methylprednisolone,
equivalent to 40 g of hydrocortisone) significantly reduced
mortality rates from 38.4 to 10.4% (110). Later studies however
reported that short courses of high-dose GC are associated
with worsened secondary infections and an increased risk of
death (111).
More recent studies have evaluated the use of GCs in doses
that are rather similar to supraphysiological stress doses (200–
300mg hydrocortisone/day) and over a longer time period
(5–7 days) (Table 2). The recommendation of 200–300mg of
hydrocortisone as a supraphysiologic dose stems from the
observation that this would be the amount of cortisol produced
by a maximally stimulated adrenal gland (117). Of note, the
“low dose” terminology used in sepsis is considered as high
dose in for example rheumatoid arthritis (118). The rationale
for the use of low-dose GCs in sepsis is to substitute the lack of
endogenous steroid activity in phases of severe stress, instead of
maximally suppressing the host immune response to infection.
Indeed, during sepsis and septic shock, CIRCI leads to insufficient
functioning of the HPA axis thereby contributing to the disease
(77). Moreover, at “lower doses,” GCs have been shown to exert
beneficial effects in terms of improvements in hemodynamics
and decrease in pro-inflammatory mediators and oxidative stress
without compromising bacterial resolution in patients with septic
shock (78, 119).
In 2002, Annane et al. showed that low doses of GCs
(hydrocortisone plus fludrocortisone) significantly reduced
mortality in patients with septic shock who did not respond
to the ACTH stimulation test (cortisol response in serum <9
µg/dl) (112). The ACTH test was used to detect people with
adrenal insufficiency. However, a second large-placebo controlled
trial (CORTICUS) using the same dosage of hydrocortisone
failed to show any survival benefit in either responders or non-
responders to ACTH (113). Differences between these two trials
comprise the lack of fludrocortisone, lower disease severity,
and later entry window for patients in the CORTICUS trial.
In 2016, the HYPRESS trial tested whether HYdrocortisone
could preemptively PREvent the development of Septic Shock in
patients with hospital-acquired sepsis, but also these results were
negative (114).
In view of all these conflicting results, the 2016 Surviving
Sepsis Campaign (SSC) guidelines recommend the use of GCs
to treat patients with septic shock if adequate fluid resuscitation
and vasopressor therapy cannot restore hemodynamic stability
(120). To improve the evidence for the use of low-dose GCs
in septic shock, two large-scale RCTs were conducted and
results were published in The New England Journal of Medicine
in 2018. Together, these two studies enrolled a total of 5041
patients outpacing all previous studies. The ADRENAL trial
(Adjunctive Corticosteroid Treatment in Critically Ill Patients
with Septic Shock) showed that treatment with hydrocortisone
did not improve 90-day survival (115). The APROCCHSS trial
(Activated Protein C and Corticosteroids for Human Septic
Shock) in contrast showed a significant reduction in mortality
rates from 49.1 to 43% (116). Both trials included patients with
septic shock; however, the APROCCHSS trial enrolled patients
with a more severe septic shock (90-day mortality rate in control
group of 49.1 vs. 28.8% in ADRENAL). Additionally, patients
in the APROCCHSS trial were enrolled earlier in the study
than patients in ADRENAL trial (time from shock onset to
randomizationwas≤24 h for all patients in APROCCHSS trial vs.
20 ± 90 h in ADRENAL trial). Lastly, patients in APROCCHSS
were bolus-injected with hydrocortisone combined with oral
fludrocortisone in contrast to patients in ADRENAL who
received a continuous infusion of hydrocortisone. Of note, both
studies used a daily dose of 200mg hydrocortisone for 7 days.
Even though the two recent trials showed either no survival
benefit or at best a small reduction in mortality with a low
dose of GCs in septic shock, the time to resolution of shock,
the time to cessation of mechanical ventilation, and the time to
discharge from the ICU were significantly shorter in the GC-
treated patients for both studies. Interestingly, low-dose GCs
were not associated with increased risks for secondary infections,
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TABLE 2 | Major randomized clinical trials investigating the effect of low-dose GC therapy in sepsis or septic shock patients.
Study Year # Patients 28-Day mortality in control group Treatment start Mortality benefit Shock reversal References
Annane et al. 2002 299 61% ≤8 h 6% 2 days (112)
CORTICUS 2008 499 36.1% ≤72 h No 3.3 days (113)
HYPRESS 2016 380 8.2% ≤48 h No No (114)
ADRENAL 2018 3,800 24.3% 20 ± 90 h No 1 day (115)
APROCCHSS 2018 1,241 38.9% ≤24 h 6.1% 2 days (116)
FIGURE 4 | HAT therapy. The function or levels of hydrocortisone, ascorbic acid, and thiamin are reduced in sepsis. Administering one of these agents as
monotherapy has shown favorable but limited outcomes. Combination of these three agents in the so-called HAT therapy may work synergistically to combat sepsis.
gastrointestinal bleeding, delayed wound healing, or myopathy,
thereby strengthening the rationale for the use of low-dose GC
therapy in sepsis.
To conclude, although GCs may have beneficial effects on the
pathophysiology of septic shock, it seems only to protect in the
sickest subgroup of septic shock patients when treated early after
shock onset. Given the low cost and limited side effects of a 7-day
GC treatment and high cost of intensive care unit stay, it is likely
that future sepsis guidelines will reinforce the use of low-dose
GCs for treatment of septic shock.
Combination Therapy
There is a significant association between the impact of early
initiation of GC therapy and improved survival (121, 122).
Delayed initiation of GC therapy limits the therapeutic value of
GCs, probably reflecting the onset of GCR after sepsis. Therefore,
adding compounds that reverses GCR opens new avenues for
GC therapy. As shown above, vitamin C enhances GC function
by reversing the effects of oxidative stress such as oxidation of
cysteine thiol groups, which affects ligand- and DNA-binding of
GR (98). Inversely, the transport of vitamin C into the cell is
mediated by the sodium-vitamin C transporter (SVCT2). Pro-
inflammatory cytokines decrease the expression of SVCT2 (123),
a process that is reversed by adding GCs (124). Additionally,
vitamin C has anti-inflammatory effects (125), improves the
integrity of the endothelium (126), and increases vasopressor
synthesis (127). It thus seems that both GCs and vitamin C
act synergistically.
As septic patients often present depletion of vitamin C,
several studies evaluated the effect of high-dose vitamin C in the
management of sepsis and septic shock (128, 129). High doses of
vitamin C however increases oxalate production, which tends to
accumulate in the kidneys of patients with renal impairment in
the form of kidney stones (130). Thiamin (vitamin B1) is able to
reduce this crystallization (131).Moreover, thiamin is an essential
cofactor for the multi-enzyme complex pyruvate dehydrogenase
(PDC), a key enzyme needed for the formation of acetyl-coA out
of pyruvate to produce energy via the Krebs cycle. Thiamin as
a monotherapy in septic shock patients with thiamin deficiency
lowered the lactate levels at 24 h and decreased mortality rates in
this subgroup of patients (132).
GCs, vitamin C, or thiamin as monotherapy have all three
shown protective but limited effects in the management of
septic shock. However, a combination of these three therapies
in a retrospective before–after study was found to prevent
progressive organ dysfunction and reduced hospital mortality
from 40.4% in the control group to 8.5% in the sepsis patients
receiving the combination therapy, with no increase in adverse
effects (101). Similar findings were observed in patients with
severe pneumonia who required admission to an ICU (hospital
mortality reduced from 39 to 17%) (102). The explanation as
to why the combination of hydrocortisone, vitamin C, and
thiamine appeared to have such a striking effect on hospital
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mortality, in comparison to the myriad of studies evaluating the
effect of using one single drug in previous sepsis trials, likely
results from the multiple and overlapping effects of all three
agents and the synergistic effect between them (Figure 4) (101).
This combination therapy, also referred to as HAT therapy, is
currently further being evaluated in a number of RCTs (133).
Alternative combination therapies such as vitamin D3 with GCs
also merit further investigation in sepsis. One study showed
that vitamin D3 lowers mortality in the severe vitamin D
deficiency subgroup of sepsis patients (134), but these results
could not be confirmed in a recent trial (135). Interestingly,
in inflammatory disorders such as psoriasis and palmoplantar
pustulosis, combining GCs with vitamin D3 appears to be more
effective than GC or vitamin D3monotherapy as these two agents
work synergistically (136, 137). Whether this is also the case for
sepsis remains to be studied.
CONCLUSION
The use of GCs as a monotherapy in sepsis remains a
matter of debate. In 2018, two large-scale RCTs evaluating
the effect of GCs in patients with sepsis or septic shock
were published, but no definitive conclusion could be drawn.
Recently, two retrospective before–after studies evaluated the
efficacy of combining GC therapy with vitamin C and thiamin
(HAT therapy). These studies presented very promising results,
yet the sample size was rather small. Therefore, results from
ongoing large randomized controlled studies are heavily awaited.
Nevertheless, these preliminary, positive results renew the hope
for GC therapy in sepsis and should encourage researchers
to explore mechanisms that counteract GCR with the aim of
reversing GCR.
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